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1. Introduction 
“An unpleasant sensory and emotional experience associated with actual or potential tissue 
damage”(Merskey & Bogduk, 1994), pain is one of the most common symptoms in cancer 
(Lorenz et al., 2006). Pain associated with head and neck cancer could result from the 
following causes (Williams & Broadley, 2009): 
 Local or metastatic disease causing infiltration, pressure or ulceration 
 Side effects from anti-cancer treatment: medication, chemotherapy, radiotherapy, 
surgery 
 Incidental causes such as infection or coexisting morbidity 
The assessment of pain should be thorough, the treatment prompt and carefully considered. 
The current international consensus is that “…the unreasonable failure to treat pain is poor 
medicine, unethical practice, and is an abrogation of a fundamental human right” (Brennan 
et al., 2007). 
Undertreatment of pain may result in patients having increased morbidity (Carr et al., 1992; 
MacIntyre 2005), increased prevalence of depression and anxiety (Brennan et al., 2005; 
Gureje et al., 1998), poor sleep (Thorpe 1993; Cleeland et al., 1996), poor concentration and 
poor personal interactions (Ferrell, 1995).  It also has massive socioeconomic costs including 
loss in productivity (Steward et al., 2003; van Leeuwen et al., 2006), work days (Brennan et 
al., 2005) and litigations (Blyth et al., 2003). 
Management options should be kept as simple and easy to follow as possible to ensure 
compliance to treatment. Patients may prefer medication in liquid form as mouth opening 
may be difficult. However it has been noted that some oral elixirs may contain alcohol, 
which cause local irritation in a patient with oral mucositis, and tablets which are crushed 
may feel gritty and unpleasant (Weissman, 1989). Also in patients with dysphagia, the 
tablets may be difficult to swallow. Suffice to say that it is extremely important to keep re-
assessing the patient to make sure that the treatment prescribed is not more unpleasant than 
the symptom itself! The clinician may need to be flexible and imaginative in finding ways 
for the patient to comply with treatment. Other routes of administration may need to be 
considered, including the use of suppositories, subcutaneous infusion pumps, nasogastric 
feeding tubes, percutaneous enteric gastric tubes and transdermal patches. 
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2. Prevalence of pain 
Despite guidelines for treatment of cancer pain available from agencies such as the WHO 
(1996, 2008) and the Expert Working Group of the European Association for Palliative Care 
(2001),  it has been shown in a recent meta-analysis involving 26 studies that nearly half of 
patients with cancer have pain that is undertreated (Deandrea et al., 2008). Another meta-
analysis showed that cancer pain prevalence is around 53%, irrespective of staging - in 
particular for patients with head and neck cancer, the prevalence is the highest of all cancers 
at 70% (Van den Beuken-van Everdingen et al., 2007). In a pan-European survey screening 
over 5000 cancer patients, 56% had moderate-to-severe pain at least monthly (Breivik et al., 
2009). Patients with brain cancer and squamous cell cancer of the head and neck were 
amongst those with the highest prevalence of pain – 90% and 86% respectively. 
The prevalence of pain at diagnosis of head and neck cancers vary from 40% to 84% (Keefe 
et al., 1986; Chaplin, 1999; Epstein, 1993; Saxena et al., 1995). A higher incidence of pain was 
noted in more advanced disease i.e. stages III or IV (Keefe et al., 1986). A recent study 
showed that a third of patients who attend head and neck cancer outpatients had pain from 
any cause within the previous seven days, with over two-thirds of those having severe pain 
(Williams et al., 2010). No specific risk factors for pain were found in this population. 
3. Aetiology of pain 
The cornerstone of effective pain management is to determine the aetiology of the pain 
(Miaskowski et al., 2005). Pain can be due to the cancer itself, as a result of anti-cancer 
treatment such as surgery, radiotherapy or chemotherapy, or pain which is wholly unrelated 
to cancer – for example, incidental arthritic pain (Table 1).  The type of pain suffered by 
patients could be nociceptive, neuropathic or mixed nociceptive and neuropathic. 
Nociceptive pain often results from tissue damage - for example tumour pressure, the 
recurrence of tumour, bony infiltration, deafferentiation or neuroma formation secondary to 
nerve damage during neck dissection, mucositis, related or unrelated infection and 
inflammation (e.g. sinusitis), osteoradionecrosis, lesions in the cervical spine causing head 
and neck pain, to name but a few causes (Chua et al., 1999; Williams & Broadley 2009).  
Some authors also distinguished myofascial pain from nociceptive per se. Talmi et al. (2000) 
in particular discussed a type of pain resulting from a musculoskeletal imbalance, and 
associated changes occuring in the shoulder as a result of surgical neck dissection and 
removal of neck muscles. They cited Fialka and Vinzenz (1988) who noted that 77% patients 
had shoulder dysfunction and strong to severe pain after radical neck dissection, and 
Krause (1992) who noted that 31% of patients develop shoulder-arm syndrome after radical 
neck dissection. Pain resulting from anti-cancer treatment is important as it may be long-
lasting and may also adversely affect compliance to continued anti-cancer treatment. 
 
Reference Pain due to 
cancer 
Pain due to 
anti-cancer 
treatment 
Pain associated 
with cancer disease 
Non-cancer 
sources of pain 
Grond et al., 1996 81% 31% 19% 7% 
Williams et al., 2010 37% 42% - 25% 
Table 1. Presumed aetiology of pain in patients with head and neck cancer 
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Neuropathic pain is pain associated with injury or disease of the peripheral or central nervous 
systems, which may result in pathophysiological changes such as ectopic (spontaneous or 
evoked) discharge by nerves, microneuroanatomical changes, central sensitization, and many 
others beyond the scope of this review (Macintyre & Schug, 2007). Neuropathic pain for 
patients with head and neck cancer may involve all sensory nerves in the face, skull, neck and 
shoulders (Vecht et al., 1992). Some common symptoms of neuropathic pain experienced by 
the patients include spontaneous continuous burning (81%), shooting pain (69%) and 
allodynia (88%) – which describes abnormal pain elicited by light touch (Sist et al., 1999; 
Merskey & Bogduk, 1994). The percentage of patients with head and neck cancer in various 
studies who were assessed to have neuropathic pain is shown in Table 2. 
 
Reference 
Neuropathic 
(Mixed neuropathic 
/nociceptive) 
Comments 
Grond et al., 1993* 28% From surgical treatment 
Grond et al., 1996 47% 377 patients  
Forbes, 1997 26%  
Vecht et al, 1992 23% 25 patients, from surgical treatment 
Sist et al., 1999 100% 25 patients, post radical-neck dissection 
Chua et al., 1999 7.5% (37.5%) 40 outpatients 
Williams et al., 2010 10% 70 outpatients 
Table 2. Numbers of patients with head and neck cancer and neuropathic or mixed 
neuropathic/nociceptive pain. * Cited by Talmi et al., 2000 
4. Assessment of pain 
Prior to commencing analgesic therapy, a detailed history and careful examination is 
required in the patient with head and neck cancer to determine the cause of the pain, and 
the potential role of anti-cancer therapy in treating the cancer and thus decreasing or 
relieving the pain. The relative impact of analgesic drugs and techniques should also be 
explored. Investigations such as radiological examinations may be required to accurately 
determine the cause of the pain.  
The assessment of pain in any patient requires attention not only to the physical and 
physiological aspects, but also to psychological, including how the pain and disease may 
impact on their quality of life (Portenoy et al., 1999). The emotional and cognitive components 
of pain may be more significant in cancer compared with non-cancer pain (Huber et al., 2007). 
In patients with head and neck cancer additional functional problems including ability to 
swallow, speech, hearing, sight etc also may need to be assessed. All of which will have an 
additional impact on their quality of life. The expertise of specialties such as psychological 
medicine, psychiatry, neurology, allied health staff and others are required to provide a multi-
disciplinary approach to pain. Palliative care medicine encompasses many of these facets of 
cancer management, and as such is an invaluable source of information and assistance. 
Patients with cancer often have more than one distinct pain syndrome (Grond et al., 1996), 
or more than one location (Valeberg et al., 2008). In 377 patients with primary head and neck 
cancer, they described their regions of pain as in Table 3. Assessment and treatment of these 
patients must then be thorough so as to not miss symptoms and potential problems. 
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Pain region  
Head/face/mouth 78% 
Cervical region 45% 
Upper shoulder/limbs  9% 
Thoracic 7% 
Lower back, lumbar spine, sacrum, coccyx 7% 
Pelvic region  1% 
Table 3. Pain regions in patients with head and neck cancer (Grond et al., 1996) 
5. Application of pain pharmacology and physiology in the clinical setting 
Pain as a subject is still under research and much is yet not understood about the 
mechanisms of chronic pain. Treatment methods of pain, particularly those of chronic and 
neuropathic pain, are still being refined. Table 4 shows some aspects of pain pharmacology 
and physiology linked to clinical relevance. 
 
Pain Pharmacology and 
Physiology 
Clinical Relevance 
Peripheral nerve injury leads to 
ectopic discharge, 
microneuroanatomical and 
phenotypical changes* 
Chronic, neuropathic pain is not easily treatable by 
conventional analgesics 
Central sensitization as a result 
of neuroplasticity* 
Treat early before persistent changes to CNS synaptic 
processing take place due to neuronal damage 
Acute severe pain post-
operatively is an important 
predictor of persistent pain* 
Acute post-operative pain need to be aggressively treated 
to prevent long term problems with persistent pain 
Evidence for pre-emptive 
analgesia is inconclusive* 
No  good evidence in humans for analgesics given pre-
painful stimulus versus post-stimulus 
Preventive analgesia to reduce 
chronic pain syndromes* † 
“Preventative analgesia” is a description of when the 
effects of the analgesics administered exceed the expected 
duration of effect of the analgesic strategy. There is some 
evidence in the effective use of ketamine and early use of 
calcitonin in preventive analgesia. 
NMDA receptor activation in 
central sensitization*‡ 
NMDA receptor antagonists, particularly ketamine, is of 
special interest, having been shown to have preventive 
analgesic effects in some circumstances 
Role of reorganisation in the 
somatosensory cortex*  
May contribute to neuropathic pain states such as 
phantom limb pain and complex regional pain syndrome 
(CRPS) 
Multimodal analgesia to 
combat central and peripheral 
plasticity† 
Use of more than one type of analgesic to treat pain 
Evidence for effectiveness of 
the multidisciplinary approach 
to pain treatment‡ 
A holistic view of the patient situation should be 
employed, involving other practitioners in pain 
management 
Table 4. Clinical relevance of pain pharmacology and physiology. (Brennan & Kehlet, 2005†; 
Macintyre & Schug, 2008*; Williams & Broadley, 2009‡) 
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6. Acute pain 
Patients with head and neck cancer may suffer from acute cancer-related, or acute anti-
cancer treatment related pain. Acute cancer-related pain may occur as a result of 
inflammatory and tumourigenic pain mechanisms such as local tumour pressure, or 
infiltration of tissues or bone, which may cause subsequent obstruction or compression of 
visceral structures or nerves and also paraneoplastic effects at distant sites (Portenoy & 
Lesage, 1999; Delaney et al., 2008). Anti-cancer treatments such as surgery, chemotherapy or 
radiotherapy can be a means of alleviating pain as the tumour is debulked, but they may 
also have side-effects causing acute pain after the treatment. 
6.1 Acute post-surgical pain 
In the patient with head and neck cancer, surgical procedures such as radical neck dissection 
or other major head and neck surgery will cause acute post-surgical pain – this is not 
unexpected by most people. The treatment of this acute post-surgical pain commences peri-
operatively by the anaesthetist administering analgesics or local anaesthetic techniques such 
as local infiltration to the wound or nerve blocks. Some patients may be given analgesics as 
a pre-medication pre-operatively. Treatment of post-surgical pain continues into the 
recovery area and onto the wards and eventually home ideally using multi-modal analgesia 
via all routes of administration, as will be discussed later in the chapter.  
Acute post-surgical pain is usually easily amenable to treatment and as such should be 
promptly and adequately treated to prevent development of chronic post-surgical pain 
(CPSP). Patients reporting high levels of acute post-operative pain and at 4 days post-
operation are at high risk of increased pain, poor global recovery with functional limitations 
and lower quality of life at 6 months post-operatively (Peters et al., 2007).  This is concordant 
with review articles by Perkins & Kehlet (2000) and Kehlet et al. (2006) citing numerous 
studies to show that acute moderate to severe post-operative pain is a predictive factor for 
CPSP. Occasionally acute post-surgical pain is difficult to treat as nerve damage occurs peri-
operatively from direct resection, bruising or stretching, particularly patients undergoing 
radical neck dissection (Talmi et al., 2000). Referred shoulder and arm pain may also occur 
(Chaplin, 1999; Talmi et al., 2000). 
6.2 Acute pain following radiotherapy and chemotherapy 
Pain following radio- and chemo-therapy in patients with head and neck cancer normally 
manifests itself as oral mucositis. However, other problems such as radiation fibrosis 
syndrome, infection and chemotherapy-induced peripheral neuropathy can also cause acute 
or chronic pain.  
6.2.1 Oral mucositis 
Radiation-induced mucositis is common in head and neck cancer patients, with increasing 
frequency due to the use of more intensive altered radiation and concurrent chemotherapy 
regimes (Rosenthal & Trotti, 2009). The incidence however will significantly vary amongst 
different treatment regimens and modalities. Oral mucositis normally becomes symptomatic 
between the second and fourth week of treatment of radio- or chemotherapy. In many 
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patients, oral mucositis is associated with considerable pain, which may lead to dose 
reductions, delays and abandonment of further anti-cancer treatments, to increases in 
healthcare costs, and impairment in the patient’s quality of life. Details of the 
pathophysiology of oral mucositis is beyond the scope of this chapter. As an outline, the 
available evidence supports the view that oral mucositis is a complex, interactive process 
involving all the tissues and cellular elements of the mucosa, with suggestions of genetic 
risks of developing mucositis (Sonis et al., 2004). Further detailed work is required to clarify 
the process.  
Pain is only one symptom of oral mucositis. Dysphagia, another common complaint, leads 
to a dependency on feeding tubes and its associated complications or parenteral nutrition, 
dehydration, micronutrient deficiencies, weight loss, and aspiration (Rosenthal & Trotti, 
2009, Sonis et al., 2004). Mucositis also leads to ulceration and subsequent infection, which 
are both additional causes of pain. In children with mucositis, it should be remembered that 
their smaller airways may prove problematic with airway compromise. Hospitalisation is 
sometimes necessary both for initial control of pain and treatment of the other complications 
already mentioned. 
Treatment of oral mucositis was recently the subject of a Cochrane Collaboration Review 
(Clarkson et al., 2008). They concluded that the evidence for allopurinol mouthwash, 
granulocytemacrophage-colony stimulating factor, immunoglobulin and human placental 
extract to improve or eradicate mucositis is weak and unreliable and requires  
further research.  
Symptomatic control of oral mucositis pain by using analgesics may be via many different 
routes. Many patients with head and neck cancer are still able to take oral analgesics, so 
the oral route should not be disregarded altogether. One must bear in mind however the 
other routes of administration, including the transdermal patch, intravenous, 
intramuscular or subcutaneous routes.  Although there is no evidence that patient 
controlled analgesia (PCA) is more beneficial than a continuous infusion method for 
controlling pain, patients using PCA used less opiate per hour, and had shorter durations 
of pain (Clarkson et al., 2008), and thus may suffer less from the side-effects of opiate 
medication. Multi-modal analgesia should also be considered. In particular, there is 
evidence that concomitant administration of adjuncts such as gabapentin is useful in 
radiation-induced mucositis (Bar et al., 2010a, 2010b).  
6.2.2 Other complications of radio- and chemotherapy 
Radio- and chemotherapy can also cause other pain syndromes in patients with head and 
neck cancer, such as radiation fibrosis syndrome, chemotherapy-induced peripheral 
neuropathy and infection.  
With fibrosis from radiation pain may occur when the skin and underlying structures 
contract. An example is “dropped head syndrome”, described by Rowin et al. in 2006 as 
one potential complication of radiation of the mantle field (neck, axillary and mediastinal 
lymph nodes). This is a late complication of radiotherapy, characterised by fibrosis and 
contractures of the anterior cervical muscles and atrophy of the posterior neck and 
shoulder girdle. 
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Chemotherapy-induced peripheral neuropathy (CIPN) is frequently a complication of 
common anti-cancer treatments, but is often under recognised and undertreated, with 
additional difficulties of it being difficult to diagnose, with no universally accepted 
assessment tools and a lack of interobserver agreement (Stephens et al., 1997 and Postma et 
al., 1998, as cited in Farquhar-Smith, 2011). As an example, docetaxel causes less CIPN than 
pacitaxel, carboplatin can also cause CIPN, but less than ciplatin (personal communication, 
Farquhar-Smith, 2011). Being neuropathic in nature, it is not easy to treat and is commonly a 
problem in the cancer survivor. There is conflicting, inconclusive evidence that anti-
neuropathic agents such as gabapentin may be effective for CIPN (Farquhar-Smith, 2011, 
quoting Tsavaris et al., 2008; Rao et al., 2007). The heterogeneous nature of CIPN with 
different anticancer therapies, resulting in distinct neuropathies adds another layer of 
complexity to its management.  
As with other complications of anti-cancer treatment, the discomfort of CIPN may impact on 
the willingness of patients to enter into future anti-cancer treatments. Additional clinician 
and patient education is required to highlight the potential problems with this syndrome 
and further research is necessary to improve current treatment options and potential 
preventative measures. 
Infections, both local and systemic, may also play a role in exacerbating pain in the patient 
with head and neck cancer. This can occur at any stage of treatment and may often present 
as a worsening pain problem. Local infections are common with patients who have head 
and neck cancer. Celluitis, localised tumour infections and orocutaneous fistulae contribute 
to more than 20% of febrile episodes in patients with head and neck cancer. Infections may 
or may not be accompanied by clinical signs such as local inflammation or systemic 
involvement with fever and leucocytosis (Bruera & MacDonald, 1986 and Hussain et al., 
1991, as cited by Williams and Broadley, 2009), particularly due to their already 
immunosuppressed state from the disease itself or the treatment already undergone. 
Treatment of the pain will be symptomatic as well as treating the infection itself. 
7. Chronic pain 
The definition of chronic pain as according to the International Association for the Study 
of Pain (IASP) is “pain which has persisted beyond normal tissue healing time”, which, in 
the absence of other criteria, is taken to be 3 months (IASP, 1986). Chronic pain may be 
accompanied by severe psychological and social disturbances. Whilst acute pain 
management focuses on the cause of the pain, the aim of chronic pain treatment is about 
managing the effects of the pain, including the physical and psychological aspects, to 
maximise the function of the patient with chronic pain (Clinical Standards Advisory 
Group, 2000).  
Chronic pain in cancer often occurs as a consequence of cancer treatment. With survival 
being the primary goal of cancer treatment, side-effects or risks to treatments such as pain 
are frequently being brushed aside as inconsequential (List et al., 2004), although it is 
essential to bear in mind - a survey of chronic pain patients in the UK revealed that the 
second most common aetiology of chronic pain was surgery (Crombie et al., 1998). 
Figure 1 shows 3 different pain transmission states: 
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1. Normal physiological pain transmission – the pain stimulus causes action potentials to 
travel from the periphery to the brain, with no neuroplasticity (“wind-up” mechanism). 
2. Nociceptive pain transmission, with both peripheral stimulation and some central 
sensitization. Pain may be persistent, but should resolve once the stimulus is 
removed/resolved. 
3. Neuropathic pain transmission. Abnormal transmission of action potentials as a result 
of “wind-up”, causing altered sensations to both noxious and normally non-noxious 
stimuli, leading to symptoms such as allodynia and other descriptions of “nerve pain” 
such as “shooting”, “burning”, “pins and needles” etc. 
 
Fig. 1. Three pain transmission states: Phase 1 - normal physiological pain transmission; 
Phase 2 - nociceptive pain transmission, with peripheral stimulation and central 
sensitization; Phase 3 - neuropathic pain transmission. Reproduced with permission, 
Williams & Broadley, 2009. 
8. Treatment of pain 
The mainstay of the management of pain in the patient with head and neck cancer is to 
target the source of the pain. According to the WHO (2008), up to 90% of cancer pain can be 
effectively managed. Pain can often be controlled with anti-cancer treatments such as 
radiotherapy, chemotherapy and surgery. Analgesic drugs and techniques are used 
concurrently to alleviate pain.  
8.1 Drug therapy  
The WHO guidelines for the treatment of cancer pain advocate a stepwise increase in drug 
dosages and drug type. The recommendation is summed up as in Table 6. 
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Head and Neck 
Tumour/Treatment 
Neuropathic Pain Syndrome 
Intraorbital  Sharp, lancinating pains in the distribution of the 
ophthalmic nerve 
Maxillary antrum Sharp, lancinating pains in the maxillary nerve 
distribution 
Infratemporal fossa Mandibular nerve distribution neuralgia, trismus, 
temporal pain 
Nasopharynx, oropharynx, 
tonsillar region, oral cancers 
Glossopharyngeal and vagal nerve distribution neuralgia 
and palsies, occipital pain radiating to vertex, referred 
pain causing otalgia, tinnitus, dental pain  
Postherpetic neuralgia Commonly affects trigeminal nerve with stabbing pains 
and hyperaesthesia 
Post-radical neck dissection Diffuse burning sensation neck and shoulders, sensation 
deficits, allodynia, shooting pain, severe shoulder pain 
and dysfunction, superficial cervical plexus neuralgia 
Chemotherapy Chemotherapy-induced neuropathic pain, causing distal 
“stocking and glove distributions”, usually symmetrical, 
predominantly sensory symptoms 
Table 5. Neuropathic pain syndromes in head and neck cancer, adapted with permission 
from Willams & Broadley, 2009 (Talmi et al., 1997; Chua et al., 1999; Sist et al., 1999; 
Farquhar-Smith 2011) 
 
WHO recommendation Comments 
By mouth Use the oral route unless contra-indicated. In the patient with 
head and neck cancer, drugs can still be taken enterally by 
nasogastric or gastrostomy tubes or rectal administration. 
Patients unable to use the enteral route could try different 
preparations such as subcutaneous, intravenously or 
transdermal patches. 
By the clock Regular administration to be given before the previous dose 
wears off. Breakthrough analgesia is not a substitute but is 
given in addition to regular. 
By the ladder Follow the WHO 3-step ladder 
For the individual There are no standard doses – the correct dose is one that 
relieves pain. Titrate dose and add adjuvant therapy as 
necessary. 
Attention to detail Individualised details such as timing, side effects, response, 
follow-up, weaning etc. Regular reviews to ensure a 
personalised treatment plan. 
Table 6. WHO guidelines for the treatment of cancer pain. (WHO, 1996) 
The WHO 3-step ladder was developed for the treatment of cancer pain (WHO, 1996). It 
encourages the clinician to assess the severity of pain, administer the appropriate 
medication, and then re-assess. The patient may then be moved up or down the ladder 
depending on the clinical assessment of his/her pain. An additional step 4 is now often 
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advocated for some patients (Figure 2). Patients often are prescribed analgesia from more 
than one step, as part of the concept of “multi-modal analgesia”. Drugs from Step 1 in 
particular have been shown to work synergistically with opioids and can often be opioid-
sparing, which helps to decrease the side-effect profile of the opioids used (Macintyre & 
Schug, 2007). 
 
 
Fig. 2. The WHO 3-step ladder, with step 4 modification 
8.1.1 WHO Step 1 – Non-opioid drugs 
Step 1 drugs on the WHO ladder consist of paracetamol (acetaminophen) and non-steroidal 
anti-inflammatory (NSAIDs) drugs only. Paracetamol is used widely for mild-to-moderate 
pain with a well-established safety profile. Its mechanism of action is surprisingly not well 
defined, for such a prevalent drug, but it is thought that paracetamol acts as a centrally-
acting cyclooxygenase enzyme inhibitor, with suggested modulations of the serotoninergic 
system and interference with peripheral delivery of β-endorphins (Remy et al., 2006). 
Paracetamol is known to act synergistically with NSAIDs and is opiate-sparing. Intravenous 
paracetamol is particularly useful for those patients who are unable to use the oral route due 
to clinical or symptomatic reasons.  
The class of NSAIDs include both non-selective cyclooxygenase enzyme inhibitors (COX-I 
and II), such as aspirin, ibuprofen, naproxen, diclofenc, and also selective cyclooxygenase II 
(COX-II) inhibitors such as celecoxib and paracoxib. Cyclooxygenase produces 
prostaglandins, which is one contributor to the peripheral inflammatory response, as well as 
playing a part in thrombosis, body salt and water homeostasis, blood pressure, and gastric 
protection (Gislason, 2009,  citing Grosser et al., 2006). There are many well known potential 
complications with NSAIDs, including renal impairment, gastrointestinal (GI) irritation, 
leading to ulceration and haemorrhage, haematologic (anti-platelet effects) and aspirin-
exacerbated respiratory disease (Risser et al., 2009). The COX-II selective NSAIDs are shown 
to have a lower incidence of problems with GI irritation compared to non-selective NSAIDs, 
however risk varies depending on the individual NSAID. An additional GI risk is a long 
plasma half-life and also the slow-release formulation (Massó González et al., 2010). The 
cardiovascular system is also affected, increasing the risk of fluid retention, oedema and 
destabilise existing heart failure. COX-II selective NSAIDs are particularly known to have 
effects on the cardiovascular system, but the rates of these events in general are so low, that 
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probably the estimates are imprecise and it is difficult to design a trial which would 
investigate this ethically and be financially viable (Trelle et al, 2011). 
8.1.2 WHO Step 2 – Weak opioid drugs 
In the UK the weak opioid drugs currently available are codeine, dihydrocodeine and 
tramadol. Weak opioids are used for mild-to-moderate pain, often in combination with Step 
1 analgesics.  
CYP2D6, an isoenzyme of the cytochrome P450 family, is important for the metabolism of 
codeine and tramadol. There are many variants of the CYP2D6 enzyme, which impact upon 
the metabolism of weak opioids (Leppert, 2011). This polymorphism results in some people 
being “poor metabolisers”, whereas some people are “extensive metabolisers”. The effects 
can be unpredictable. One metabolite of codeine is morphine, but the analgesic effect of 
codeine is approximately 1/10th of morphine analgesia. Tramadol is centrally-acting, on 
opioid receptors, but also on other mechanisms such as noradrenaline and serotoninergic 
reuptake mechanisms (Macintyre & Schug, 2007). Both mechanisms are implicated in 
neuropathic pain pathways. The metabolism of dihydrocodeine is not affected by CYP2D6 
(Leppert, 2011). 
Some clinicians prefer to go directly from Step 1 to Step 3, to avoid the potential for 
uncertainty with CYP2D6 polymorphism. Instead, strong opioids are titrated carefully to the 
patients’ needs. 
8.1.3 WHO Step 3 – Strong opioid drugs 
Strong opioid drugs include morphine, diamorphine, oxycodone, fentanyl, which are mu-
opioid receptor agonists, and also partial agonists such as buprenorphine. These Step 3 
analgesic drugs are used for moderate-to-severe pain.  
The most commonly used drug is morphine, of which there are several preparations. For 
patients with head and neck cancer who find tablets difficult to swallow, there are elixirs 
which can be taken orally or passed down a feeding tube. Both immediate release 
preparations and sustained-release preparations are available in elixir form.  
Other forms of strong opioid drugs include the transdermal patch for fentanyl or 
buprenorphine. Buccal preparations of fentanyl are also available – as a lozenge or lollipop 
to be sucked, or a tablet which slowly dissolves. The type of preparation most suitable for 
the patient depends on their particular circumstances – for example, a head a neck cancer 
patient who has painful oral mucositis, with a persistently dry mouth may find it 
uncomfortable to use lozenges or buccal tablets, and may prefer transdermal patches, or 
intravenous or subcutaneous patient controlled analgesic devices (PCAs).  
Some patients become resistant or tolerant to strong opioids, particularly if they have 
required Step 3 medication for a prolonged period of time. In this case it may be necessary 
to change to a different drug. Any other strong opioid may be chosen - methadone is good 
option which is often forgotten. It is particularly convenient as a once daily administration 
due to its long half life. 
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The potential adverse effects of opioid medication, both weak and strong, must not be 
overlooked. The most common problems are constipation, nausea and vomiting, and 
sedation. For constipation, the patient should be advised to keep well hydrated, mobilise, 
and if prescribed opioid for more than a few days, all patients should also be prescribed 
laxatives – a stool softener and a bowel stimulant. Dose reduction of the opioid does not 
help with constipation. Newer agents such as the combined oxycodone/naloxone, and 
opioid antagonists such as methylnaltrexone have been shown to be effective in this regard 
(Clemens et al., 2011; Candy et al., 2011). Nausea and vomiting is perhaps the most 
unpleasant side-effect for the patient. Numerous classes of anti-emetics are available, and as 
with analgesic drugs, a combination of anti-emetics acting at a combination of sites may be a 
more effective method than single treatment (Macintyre & Schug, 2007). Mild sedation and 
cognitive impairment are common side effects of opioid therapy, however tolerance 
develops quickly. Sedation can be a warning sign of excessive opioid therapy, and will 
almost always precede respiratory depression. A decrease in respiratory rate is actually a 
late and unreliable sign of opioid-induced respiratory depression. Both sedation score and 
respiratory rate should be monitored, particularly when starting patients on new 
medications, in the acute setting. 
8.1.4 WHO additional Step 4 – Adjuvant drugs and interventions  
Step 4 is a modification commonly proposed to the original 3-step WHO analgesic ladder 
(Vargas-Shaffer, 2010). Consisting of both drug and interventional therapy, step 4 adjuncts 
may be added at any point, with any combination of other steps. The adjuvant drugs 
proposed are those that are now commonly used for chronic or neuropathic pain, including 
anti-depressants (amitriptylline, nortriptylline), anti-convulsants (gabapentin, pregabalin), 
NMDA-receptor antagonists (ketamine), steroids, capsaicin and so forth. Local anaesthetics 
are also included in this group – either as part of an intervention such as local anaesthetic 
infiltration/nerve blocks, or as a transdermal patch (lidocaine patch). As we have already 
seen, patients with head and neck cancer will often have neuropathic pain, and chronic pain. 
The addition of a step 4 adjunct may help in the treatment of their pain, and may also 
decrease the amount of opioids necessary to help control pain. 
8.2 Interventional therapy  
In the patient with head and neck cancer, interventional therapy for pain caused by cancer 
or cancer treatment is now not longer at the forefront of pain management. It was not 
possible to use single nerve blocks to relieve pain, as sensory innervations in the head and 
neck region typically arises from multiple cranial or cervical nerves. Numerous other 
methods have been tried with reasonable success. Examples include cervical plexus block 
(Dwyer 1972), lumbar CSF morphine injections (Sullivan 1987), long-term intraventricular 
infusion of morphine (Dennis & DeWitty, 1990) and intrathecal administration of 
analgesics (Crul et al., 1994). However, these interventions described are not without 
potentially very serious complications. The modern analgesics and their methods of 
delivery are now so well established such that these interventions are largely no  
longer performed. 
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8.3 Characteristics of studies investigating pain in patients with head and neck 
cancer 
Study 
(Number of 
patients) 
Cancer type Duration of 
follow-up 
Prevalence of head and neck pain 
Bjordal (N = 126)  
1992 
Head and neck 
cancer 
None 18% ("quite a bit" or "very much" 
pain) 
Chaplin and 
Morton (N = 93) 
1998 
Newly diagnosed, 
curable head and 
neck cancer 
2 years 48% at diagnosis (8% severe) 
25% at 12 months (3% severe) 
26% at 24 months (4% severe) 
Forbes (N = 38) 
1997 
End-stage head 
and neck cancer  
None 79% (26% neuropathic) 
 
Keefe (N = 30) 
1986 
Head and neck 
cancer (100% 
squamous cell 
carcinoma) 
3-6 weeks after 
initial evaluation  
 
2-3 months after 
initial evaluation  
 
40% at initial evaluation 
50% at final evaluation 
Olson (N = 51) 
1978 
Head and neck 
cancer, undergone 
surgical treatment 
previously 
Unknown 32-39% mild to moderate (8% 
moderate) 
No patients reported severe pain 
Robertson and 
Hornibrook  
(N = 522)  
Head and neck 
cancer (90% 
squamous cell 
carcinoma) 
 8% to 66%, depending on cancer type 
Saxena 1995 
 (N = 117)  
Head and neck 
cancer (90% 
clinical stage III or 
IV) 
 84% 
(55% moderate to severe, 50% of 
whom had unrelieved pain) 
Talmi (N = 62) 
1997 
Terminal head and 
neck cancer (87% 
squamous cell 
carcinoma) 
None 77% 
Epstein (N = 34) 
1993 
Head and neck 
cancer pre-/post-
radiotherapy (91% 
squamous cell 
carcinoma) 
6-12 months 82% at diagnosis 
100% at midpoint of treatment 
46% 6-12 months after treatment 
Weissman  
(N = 14) 1989 
Newly diagnosed 
head and neck 
cancer patients 
undergoing 
radiotherapy 
Unknown 29% before treatment 
100% during treatment 
(moderate to severe pain on 37% of 
treatment days) 
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Talmi (N = 88)  
2000 
 
Head and neck 
cancer 
1-8 months 
(prospective) 
 
>2 years 
(retrospective) 
 
6-24 months 
(retrospective) 
85% after neck dissection; 3% after 2 
months 
 
0% 
 
 
15% 
Terrel (N = 175) 
1999 
Head and neck 
cancer  
None Unknown 
Chua (N = 40) 
1999 
Head and neck 
cancer (83% 
squamous cell 
carcinoma; 60% T3 
or T4) 
 100% at presentation 
(severe in 52%) 
 
Grond (N = 167) 
1993 
Head and neck 
cancer 
Unknown 100% at referral 
9. Holistic care 
Aside from direct treatment of the cancer itself by surgery, radiotherapy or 
chemotherapy, one must remember that treatment of the patient with head and neck 
cancer should always be undertaken in a holistic manner. As cancer treatments are 
improving, so too are the rates of cure and length of remission. `Cancer survivorship’ 
issues such as quality of life, good pain and symptom control are important aspects of 
holistic care that should be prioritised (World Health Organisation [WHO], 1996) - the 
patient may debilitated for a long time with pain.  
Holistic care in patients with head and neck cancer involves not only being concerned about 
the practical aspect of physical problems, but also the less `medical’ problems of 
psychological distress and social aspect of cancer as a disease, in particular the aesthetic 
appearance of head and neck cancer or anticancer treatment causing disfigurement. The 
functional aspect of having cancer in this region also requires particular care – speech and 
swallow may well be affected, as well as the possibility of requiring medical adjuncts such 
as the tracheostomy. This in turn will clearly have an effect on the psychosocial state of the 
patient with head and neck cancer. These symptoms may or may not be directly mentioned 
by the patient, and it may take a clinician who pays attention to detail to elicit this 
information. By identifying and resolving issues quickly, holistic needs assessment and care 
allows the opportunity for clinicians to make a huge difference to the overall experience of 
cancer, and the potential to improve outcome. Patients are also allowed to be fully engaged 
in their own care, thus feel empowered to support self-management of their condition 
(National Cancer Action Team, 2010). 
Symptomatic control is relevant during all stages of the cancer, be it at diagnosis, during 
treatment for cure or palliation, after anti-cancer treatment, at palliation, or even once 
`cured’. Commonly pain with head and neck cancer will occur as a result of anti-cancer 
treatment, as well as due to disease progression. Sometimes the most effective method of 
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symptom management or palliation may be further anticancer treatment. The potential 
adverse effects must then be weighed up when considering the expected benefit to 
undergoing therapy for pain. The patient and family members should be well informed 
before making a joint decision with the clinician to undergo any further treatment. 
Treatment of pain in the patient with head and neck cancer may well be adequately 
managed by an experienced clinician. However many studies quoted by Brennan et al (2007) 
showed that many clinicians are not comfortable in prescribing opioids, having a lack of 
knowledge of pharmacology of the relevant drugs and experience of pain management. The 
Pain Management or Palliative Care Teams are experts in the hospital in this regard and 
timely advice should be sought when problems arise to prevent complications developing 
further down the line. Quite as importantly, bearing in mind the subjective nature of the 
pain as a whole, the clinician needs to believe in patients in their descriptions of their pain, 
and take action to help alleviate the pain. 
10. Conclusion 
Patients with head and neck cancer will often suffer from pain, resulting from the cancer 
itself, anti-cancer treatment, or wholly unrelated causes. A high percentage of patients will 
suffer from neuropathic pain, or mixed nociceptive and neuropathic pain, which may be 
difficult to treat. Many patients with head and neck cancer will also have pain in more than 
one location. When treating these patients, it is vital to carefully assess and determine the 
aetiology of their pain in order to effectively treat their symptoms. Early treatment is 
advised to help avoid progression into chronic pain and will further complicate treatment 
strategies. A multi-modal, multidisciplinary approach to pain management encapsulates the 
concept of holistic care and may make a huge difference to the experience of cancer for the 
patient. We should aim to empower our patients and encourage them to take ownership of 
their pain issues. By doing so, we will be positively contributing to the quality of the patient 
journey with cancer.  
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Head and Neck Cancer provides an interesting and comprehensive overview of all aspects of head and neck
cancer including overviews of the disease, basic science aspects pertaining to the disease, diagnosis,
treatment and outcomes for patients with this disease. The chapters written by world renowned experts cover
the entire discipline of head and neck oncology and include discussions of regional disparity is, advances in
basic science understanding, advances in her radiotherapy, chemotherapy and targeted agents as well as a
focus on reconstruction, prostheses, and aspects of quality of life and health outcomes. The book is designed
to be both practical and comprehensive for every physician treating his complex disease.
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